): The objectives Of the Clinical Oncology Research Development Program are especially suited to the environment within New York University Medical Center. The NCI-designated Kaplan Cancer Center, in its 22nd year, is focusing on the amalgamation of clinicians within the traditionally rich basic science programs. Young faculty in clinical departments are eager to interact with such programs to develop expertise in translating basic science observations into new clinical approaches that will directly benefit cancer patients. Availability of a K12 grant and associated curriculum are in part responsible for the presence of qualified and motivated c l inical oncologists with a primary modality orientation in medical, radiation, surgical and pediatric oncology. The applicants now seek expansion and renewal of this opportunity to have qualified clinical oncologists immersed in an environment of exciting peer-reviewed, clinically relevant, basic science research programs. Their curriculum is divided into an initial (phase I) and intense (phase II) research component with concurrent clinical research and didactic components. Phase I consists of experiences designed to give the trainee an operational relationship with a basic science laboratory. Review at 6 months marks the entry into a second phase of research project selection that ultimately leads to independent research activities. Ongoing is involvement in clinical research activities suitable to the individual awardee focusing on acquiring practical clinical trials methodology. The didactic component includes courses in molecular biology, epidemiology, and biostatistics and attendance at seminars, conferences, and colloquia. The clinical and basic science faculty have track records of peer reviewed and research training. One to two trainees per year are expected to enter the program and be supported for 2-3 years. A multidisciplinary Advisory Committee similar to a graduate student training committee selects the candidates and their research projects, reviews their progress quarterly and evaluates individual trainees and the program as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA001713-07
Application #
2769712
Study Section
Special Emphasis Panel (ZCA1-GRB-J (01))
Program Officer
Gorelic, Lester S
Project Start
1997-09-30
Project End
2002-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Wen, Yong Hannah; Shi, Xiuquan; Chiriboga, Luis et al. (2007) Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 18:1387-93
Afonja, Olubunmi; Juste, Dominique; Das, Sharmistha et al. (2004) Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 23:8135-45
Afonja, Olubunmi; Raaka, Bruce M; Huang, Ambrose et al. (2002) RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21:7850-60
Shamamian, P; Schwartz, J D; Pocock, B J et al. (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189:197-206
Demaria, S; Volm, M D; Shapiro, R L et al. (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025-30
Mazzieri, R; Munger, J S; Rifkin, D B (2000) Measurement of active TGF-beta generated by cultured cells. Methods Mol Biol 142:13-27
Jacobson, D R; Fishman, C L; Mills, N E (1995) Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Ann Oncol 6 Suppl 3:S3-8
Mills, N E; Fishman, C L; Rom, W N et al. (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55:1444-7
Mills, N E; Fishman, C L; Scholes, J et al. (1995) Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 87:1056-60